Trial Profile
Safety and Tolerability of Single Ascending Doses (SAD) of a Novel Engineered Cationic Peptide PLG0206 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Dec 2021
Price :
$35
*
At a glance
- Drugs PLG 0206 (Primary)
- Indications Bacterial infections; Bone and joint infections
- Focus Adverse reactions; First in man
- Sponsors Peptilogics
- 01 Dec 2021 According to a Peptilogics media release, results from this trial were published in peer-reviewed journals Antimicrobial Agents and Chemotherapy (AAC) and Microbiology Spectrum.
- 01 Dec 2021 Results published in the Peptilogics Media Release.
- 22 Nov 2021 Results published in the Antimicrobial Agents and Chemotherapy